Moderna Phase 1 results show coronavirus vaccine safe, induces immune response(reuters.com)
reuters.com
Moderna Phase 1 results show coronavirus vaccine safe, induces immune response
https://www.reuters.com/article/us-health-coronavirus-moderna/moderna-phase-one-results-show-coronavirus-vaccine-safe-induces-immune-response-idUSKCN24F2SW
2 comments
Could you explain the snippet in plain English? Thanks!
They stopped the treatment for one person in the experiment group treated with 25 microgram dosage, because they showed a side-effect of itchy skin.
There is a bunch of white blood cells that produce things called cytokines which act as messengers on immune response. When you want to kill a pathogen you produce Th1. When you produce too much of it you risk killing your own tissue to cancel that you produce Th2. A balance between Th1 and Th2 is needed so that you don't kill yourself while trying to kill pathogens.
P.S.: not an immunologist.
There is a bunch of white blood cells that produce things called cytokines which act as messengers on immune response. When you want to kill a pathogen you produce Th1. When you produce too much of it you risk killing your own tissue to cancel that you produce Th2. A balance between Th1 and Th2 is needed so that you don't kill yourself while trying to kill pathogens.
P.S.: not an immunologist.
> unsolicited adverse event ...
... as opposed to a solicited adversity? :)
... as opposed to a solicited adversity? :)
Oxford is set to publish its results in The Lancet on Jul 20[0]. Would be interesting to see the differences and how these two compare (there must be something based on which we could say one is better than the other?)
[0] https://www.nbcnews.com/health/health-news/covid-19-vaccine-...
[0] https://www.nbcnews.com/health/health-news/covid-19-vaccine-...
Some interesting snippets:
“one participant in the 25-μg group was withdrawn because of an unsolicited adverse event, transient urticaria, judged to be related to the first vaccination.”
Also probably more important than antibodies: “The 25-μg and 100-μg doses elicited CD4 T-cell responses (Figs. S9 and S10) that on stimulation by S-specific peptide pools were strongly biased toward expression of Th1 cytokines (tumor necrosis factor α > interleukin 2 > interferon γ), with minimal type 2 helper T-cell (Th2) cytokine expression (interleukin 4 and interleukin 13). CD8 T-cell responses to S-2P were detected at low levels after the second vaccination in the 100-μg dose group (Fig. S11).”